RSV Seasonal Vaccine Introduction and Growth Strategy
Four focused therapeutic areas
Two thirds of our development portfolio comes from infectious diseases and HIV
Infectious
Diseases
HIV
Respiratory/
Immunology
Oncology
Pioneering novel platform technologies to
help prevent and treat seasonal respiratory
viruses, bacterial, fungal and chronic viral
infections
Arexvy1
MenABCWY
Pneumococcal 24-valent
mRNA Seasonal influenza/COVID-19
Shingrix
Herpes simplex virus
gepotidacin
Brexafemme
Novel treatment and prevention options to
significantly improve the patient experience
Long-acting and ultra-long acting
Next-generation cabotegravir
N6LS (bNAb²)
3rd generation INSTI³
Capsid inhibitor
Slow disease progression, address
treatment resistance and reduce signs and
symptoms of disease
depemokimab
camlipixant
Nucala (COPD)
GSK4532990 (NASH5)
Seeking solutions for blood and women's
cancers and break-throughs in immuno-
oncology
momelotinib
Jemperli
cobolimab
CD226 axis
tebipenem
bepirovirsen
gonorrhoea
Enabled by advanced technology and data platforms with targeted business development
GSK
Note: select pipeline programmes shown
1. Respiratory syncytial virus in older adults 2. Broadly neutralising antibody 3. Integrase strand transfer inhibitor 4. Chronic obstructive pulmonary disease 5. Non-alcoholic steatohepatitis
11View entire presentation